Benzodiazepine and cyclopyrrolone reduction in general practice--does this lead to concomitant change in the use of antipsychotics? A study based on a Danish population. J. Affect. Disord. 2010, 126, 293-298.Jorgensen VR. Benzodiazepine and cyclopyrrolone reduction in general practice -does this...
WO2002044183A2 2002-06-06 BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS WO2002062804A1 2002-08-15 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS WO2002079134A1 2002-10-10 PROCESS FOR THE MANUFACTURE OF PHENYLACETIC ACID DERIVATIVES WO2002085458A2 2002-10-31 USE OF ...
1,5-Benzodiazocines have attracted much interest as homologs of 1,4-benzodiazepine drugs, and several efficient cyclization methods have been developed. The diamine (289; R = H), available by several routes from the aminobenzophenone, cyclizes slowly in hot pyridine, but treatment of the halid...
Additionally, the guanidine compounds described herein can be used in combination with at least one other therapeutic agent, such as Bz-423 (a benzodiazepine compound as described in U.S. Pat. Nos. 7,144,880 and 7,125,866, U.S. patent application Ser. Nos. 11/586,097, 11/585,492, ...
No serious side effects developed in patients in whom drug use was reduced. Conclusion: The intervention was effective in reducing the use of benzodiazepine and cyclopyrrolone agents in general practices in a large municipality in Denmark. It is recommended that this intervention be introduced into ...
No serious side effects developed in patients in whom drug use was reduced. CONCLUSION: The intervention was effective in reducing the use of benzodiazepine and cyclopyrrolone agents in general practices in a large municipality in Denmark. It is recommended that this intervention be introduced into ...
WO2009104819A1 2009-08-27 BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION WO2010014054A1 2010-02-04 INHIBITORS OF PROTEIN PRENYLTRANSFERASES WO2010028192A1 2010-03-11 COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS WO2010065117A1 2010-06-10 INHIBITION OF HDAC2 TO PROMOTE...
In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing harmful side effects, provided that such larger doses are first divided into several small doses for administration ...